External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology Angiogenesis 2024
Roche and Genentech at

Angiogenesis 2024

February 03 - February 03
Virtual
Angiogenesis.2024.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Feb 3 / Roche and Genentech
Microperimetry Endpoints: An Updated Analysis of the Lampalizumab Clinical Trial Data
Microperimetry is an established technique to assess visual function over time used in clinical trials in eyes with geographic atrophy due to non-exudative age-related macular degeneration. Change in retinal sensitivity at perilesional points has been shown to demonstrate greater sensitivity compared to the traditional method, which analyzes the average sensitivity across all points. For glaucoma treatments, the FDA suggests that clinically meaningful mean improvement of ≥7 dB post treatment from baseline in 5 or more predefined loci (areas), sustainable over time, is an acceptable endpoint. Using this threshold, we assessed time to 7-dB loss averaged over at least 5 or more predefined loci in the perilesional area in the lampalizumab MP population and the feasibility of using these endpoints for future clinical trials.
Ophthalmology Age Related Macular Degeneration ANGIOGENESIS-2024

Sign up or login to unlock the full suite of MEDICALLY features
Feb 3 / Roche and Genentech
Emerging Imaging and Biological Markers Supporting Angiopoietin-2 in nAMD and DME
This presentation reports the results of analyses from the YOSEMITE/RHINE and TENAYA/LUCERNE trials that evaluated clinical biomarkers of dual Ang-2/VEGF-A inhibition with faricimab▼ vs anti-VEGF inhibition alone with aflibercept. Biomarkers that were assessed included CST, intraretinal fluid, retinal pigment epithelial detachments, macular leakage, hyperreflective foci, and epiretinal membranes.
Ophthalmology Diabetic Macular Edema Neovascular Age Related Macular Degeneration ANGIOGENESIS-2024

Sign up or login to unlock the full suite of MEDICALLY features
Feb 3 / Roche and Genentech
Targeting Ang2 and VEGF - Biology, Pharmacokinetics and Latest Clinical Data in nAMD and DME
This presentation summarizes the results of faricimab▼ phase 3 trials, TENAYA/LUCERNE and YOSEMITE/RHINE, for the treatment of nAMD and DME respectively. Data presented demonstrates that dual Ang-2/VEGF-A inhibition with faricimab▼ improves disease fluid control with extended durability Vs anti-VEGF inhibition alone and may allow for potential interval extension to Q20W dosing.
Ophthalmology Diabetic Macular Edema Neovascular Age Related Macular Degeneration ANGIOGENESIS-2024
05:40 PM
Duration 10mins Virtual
Microperimetry Endpoints: An Updated Analysis of the Lampalizumab Clinical Trial Data
Ip M
Ophthalmology | Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:50 PM
Duration 10mins Virtual
Targeting Ang2 and VEGF - Biology, Pharmacokinetics and Latest Clinical Data in nAMD and DME
Lim J
Ophthalmology | Diabetic Macular Edema - Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 PM
Duration 10mins Virtual
Emerging Imaging and Biological Markers Supporting Angiopoietin-2 in nAMD and DME
Singh R
Ophthalmology | Diabetic Macular Edema - Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:10 PM
Duration 10mins Virtual
Faricimab▼ in RVO: 72-Week Results From the BALATON and COMINO Phase 3 Studies
Tadayoni R
Ophthalmology | Central Retinal Vein Occlusion - Branch Retinal Vein Occlusion

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:20 PM
Duration 10mins Virtual
Voyager Study- Update on Faricimab▼ in the Real World
Guymer R
Ophthalmology | Diabetic Macular Edema - Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:10 AM
Duration 10mins Virtual
The Path Forward for PDS: Technical Data Supporting Device Improvements and Septum Dislodgement Mitigation
Pieramici D
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:20 AM
Duration 10mins Virtual
The Impact of Continuous Delivery of Ranibizumab With PDS on Retinal Nonperfusion in Diabetic Retinal Disease
Campochiaro P
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.